Harvest of Human Mesenchymal Stem Cells from Microcarriers

Traditional planar culture formats are being superceded by microcarriers for large-scale cell therapy manufacturing.
Sep 15, 2017
Volume 2017 eBook, Issue 2, pg 23–26

Hundreds of clinical trials are currently underway testing the merits of cell therapies, as evidenced by the clinicaltrials.gov database and highlighted by the Alliance for Regenerative Medicine. A number of trials and commercially marketed products use adult, multipotent cells such as human mesenchymal stem/stromal cells (hMSCs). Large-scale industrialized production of these cells is necessary to continue their advancement through human clinical trials and commercialization as therapeutics. However, achieving this level of production while meeting rigorous quality standards will depend on further progress in the areas of cell culture and scale-up, characterization, enrichment, and purification to deliver a consistent and reproducible supply of cells. 

Read this article from BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook.

View other articles in BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook.

Article Details

BioPharm International
eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 23–26

Citation

When referring to this article, please cite it as A. Schnitzler et al., "Harvest of Human Mesenchymal Stem Cells from Microcarriers," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).

native1_300x100
lorem ipsum